Syngene International Q4 Results: Profit Up 5.5% At Rs 188.6 Crore, Revenue Falls
Syngene International Ltd.'s consolidated net profit rose 5.54% in the fourth quarter of financial year 2024, and beat analysts' estimates.
The contract research and manufacturing services firm posted a profit of Rs 188.6 crore in the quarter-ended March, in comparison with Rs 178.7 crore in the year-ago period, according to an exchange filing on Wednesday. Analysts tracked by Bloomberg had estimated a profit of Rs 155.7 crore.
Syngene Q4 FY24 Highlights (Consolidated, YoY)
Revenue down 7.8% to Rs 916.9 crore vs Rs 994.4 crore (Bloomberg estimate: Rs 1,024 crore).
Ebitda rose to Rs 316.9 crore vs Rs 318.3 crore (Bloomberg estimate: Rs 314 crore).
Margin at 35% vs 32% (Bloomberg estimate: 30.7%).
Net profit up 5.54% at Rs 188.6 crore vs Rs 178.7 crore (Bloomberg estimate: Rs 155.7 crore).
“While the fourth quarter performance came in lower than expected, the underlying driver reduced demand for research and development services within US biotech stemming from a difficult funding environment—is well-understood and already showing positive signs of recovery," said Jonathan Hunt, managing director and chief executive officer at Syngene International.
"Looking ahead, we expect revenue growth in fiscal year 2025 to be in the range of high single-digits to low double-digits, with momentum building up during the year. We expect the Ebitda margin to be similar to the level delivered in fiscal year 2024 and PAT growth in single digits," he said.
Shares of Syngene International closed 1% lower at Rs 694.20 apiece on the BSE, as compared with a 0.16% advance in the benchmark Sensex.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
